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Abstract. α-Synuclein is the major constituent of Lewy bodies and Lewy neurites in Parkinson’s disease (PD) and dementia with
Lewy bodies (DLB). Relatively little is known about the exact mechanism of α-synuclein deposition and fibrillization in these
α-synucleinopathies. In order to better understand the pathogenesis of α-synucleinopathies it is important to identify molecules
that regulate the fibrillization of α-synuclein. Since it has been demonstrated that heparan sulfate proteoglycans (HSPGs)
and glycosaminoglycans (GAGs) promote the conversion of non-fibrillar amyloid β-protein (Aβ) into neurotoxic fibrillar Aβ
in Alzheimer’s disease, they might also be involved in α-synuclein aggregation. It was the aim of our study to examine the
distribution pattern of these macromolecules in PD brains and the possible association with Lewy bodies and Lewy neurites.
Although HSPGs clearly colocalized with senile plaques, we were unable to identify HSPGs or GAGs in Lewy bodies and Lewy
neurites and therefore concluded that it is likely that α-synuclein fibrillization and stabilization occurs independently of the
presence of HSPGs or GAGs.
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1. Introduction
The neuropathological diagnosis of both Parkinson’s
disease (PD) and dementia with Lewy bodies (DLB)
relies on identification of intraneuronal Lewy bodies
and Lewy neurites [8]. These inclusions occur exclu-
sively in specific types of neurons of select regions of
the human nervous system [2,31]. It was demonstrated
that α-synuclein is the major constituent of Lewy bod-
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ies and Lewy neurites, and that anti-α-synuclein anti-
bodies immunostain Lewy bodies and Lewy neurites
in PD and DLB brains [1]. α-Synuclein is also the
main component of the glial and neuronal inclusions of
multiple system atrophy [13].
α-Synuclein was first isolated and purified from the
electric organ of Torpedo californica [17]. It was sug-
gested that α-synuclein plays a role in neuronal plastic-
ity because its expression in songbirds increased dur-
ing learning [10]. In normal functioning neurons, α-
synuclein is synthesized in the perikaryon and trans-
ported to presynaptic terminals. α-Synuclein is usually
localized in synaptic boutons, typically in close prox-
imity of, or bound to synaptic vesicles [17]. The native
protein likely plays a role in maintenance and stabi-
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lization of fully matured synapses [18]. However, its
normal localization seems to be disturbed in PD/DLB,
where reallocation occurs resulting in accumulation of
α-synuclein in the cell body and in more proximal parts
of the neurites. Monomeric α-synuclein can form fib-
rils in solution [10,12]. During this fibrillization pro-
cess, native unfolded α-synuclein undergoes conforma-
tional changes resulting in partially folded intermedi-
ates and toxic protofibrils. It has been reported that hep-
aran sulfate proteoglycans (HSPGs) and glycosamino-
glycans (GAGs) promote the conversion of non-fibrillar
Aβ into neurotoxic fibrillar Aβ [3,5,23] and may pro-
tect Aβ against proteolytic degradation [5,22]. Further-
more, HSPGs/GAGs have consistently been found in
all kinds of amyloid, regardless of the specific type of
amyloidogenic protein deposited [23,26–30]. There-
fore, it might be expected that these complex macro-
molecules play a similar role in α-synuclein fibrilloge-
nesis and stabilization. It was the aim of our study to
examine the distribution pattern of HSPGs and GAGs
in PD brains in order to collect evidence for a specific
in vivo association of HSPGs/GAGs with α-synuclein.
2. Materials and methods
2.1. Autopsy material
Brain tissue from patients with clinically diagnosed
and neuropathologically confirmed PD (with or with-
out dementia) was obtained at autopsy. All brains
displayed the presence of α-synuclein-immunoreactive
Lewy bodies and Lewy neurites, while at the same time
being free of intracytoplasmic inclusions related to non-
PD α-synucleinopathies. After the routine autopsy pro-
cedure, tissue samples from the anterior cingulate cor-
tex were obtained and snap frozen in liquid nitrogen.
Cingulate cortex sections of 10 PD patients (7 male, 3
female) were investigated for the presence of HSPGs
and GAGs (age 74.8 ± 7.9 years; post mortem delay
20.1± 4.2 hours). This study was conducted with due
regard for the restrictions of the Dutch legislation on
the use of human tissue material for research purposes
(informed consent was obtained of a legal representa-
tive of the patient). Samples were anonymized leaving
only clinical data accessible.
2.2. Antibodies
Mouse monoclonal antibody synuclein Ab-2
(syn211, NeoMarkers, Fremont, CA), a highly spe-
cific mAb for α-synuclein that does not cross-react
with β- and γ-synuclein, was used as primary anti-
body. Polyclonal antibody 40-4, directed against Aβ
(generous gift of Dr. W.E. van Nostrand, Stony Brook,
NY [7]) was used to demonstrate the presence of se-
nile plaques. Additionally, specific antibodies directed
against heparinase-digested HSPGs (3G10), heparan
sulfate side-chains (JM13, JM403), agrin core protein
(JM72) and glypican-1 core protein (S1) were used to
study the expression of these molecules in PD brains.
The characterization of these antibodies has been de-
scribed in previous reports [6,24]. Anti-glypican-1 (S1)
and anti-agrin (JM72) antibodies were selected because
both mAbs strongly stain a variety of amyloidogenic
lesions such as neurofibrillary tangles, senile plaques
and amyloid-laden vessels. We used biotin-labeled
horse anti-mouse as secondary antibody with the ex-
ception of primary incubations with JM13 and JM403,
in which case biotin-labeled goat anti-mouse IgM was
used. All secondary antibodies and the avidin-biotin-
peroxidase complex (ABC) were obtained from Vector
(Burlingame, CA).
2.3. Immunohistochemistry
For immunohistochemical double-staining, 4 µm
cryosections were air-dried, fixed in acetone for 5 min-
utes, subsequently for 5 minutes in acetone containing
0.15% H2O2 to block endogenous peroxidase activ-
ity, and preincubated for 30 minutes with 20% normal
horse serum with the exception of staining with JM13
and JM403 in which case we used 20% normal goat
serum. Sections were incubated overnight at 4◦C with
either 3G10, JM13, JM403, S1 or JM72 at concentra-
tions of 10 µg/ml. In case of staining with 3G10, sec-
tions were pretreated with 50 mU heparitinase (hepari-
nase III, EC 4.2.2.8; Sigma Chemical Co., St Louis,
MO) diluted in 10 mM HEPES and 2 mM CaCl2 (pH
7.0) at 37◦C for 1 hour. Subsequently, sections were
incubated with either biotin-labeled horse anti-mouse
antibody in case of primary staining with 3G10, JM72
and S1 or biotin-labeled goat anti-mouse IgM in case
of primary staining with JM13 and JM403, for 30 min-
utes at room temperature and with avidin-labeled Texas
Red for 45 minutes. Between incubation steps, sections
were thoroughly washed with phosphate buffered saline
(PBS). After the last rinse in PBS, sections were first
incubated with a mixture of rabbit anti-mouse alkaline
phosphatase and rabbit anti-mouse horse radish perox-
idase for 30 minutes (dilution 1:20), to block residual
free binding sites on the mouse antibodies from the
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Fig. 1. Immunofluorescence staining of Lewy bodies, Lewy neurites and senile plaques in sections from PD brains for α-synuclein (mAb Ab-2,
green) (A, B), HSPG core protein (3G10, red) (A and D), HSGAG (JM403, red) (B) and Aβ (pAb 40-4, green) (C) In A nuclei were stained
blue. Cortical Lewy bodies and Lewy neurites are stained by the anti-α-synuclein antibody. Both 3G10 and JM403 strongly stained the cerebral
(micro)vasculature. Neither HSPG core-protein nor HSGAGs colocalized with α-synuclein (A, B), whereas HSPG core-protein was present in
Aβ-positive senile plaques (E). Original magnification 630 x.
first cycle. The success of this blocking procedure was
verified by omitting secondary antibodies from the first
cycle. Then, sections were washed with PBS and in-
cubated with either anti-α-synuclein Ab-2 or anti-Aβ
40-4 at a concentration of 10 µg/ml. Finally, sections
were incubated with FITC-labeled sheep anti-mouse
or swine anti-rabbit antibodies, respectively, for one
hour at room temperature. Selected sections were also
incubated with ToPro-3 for nuclear staining (dilution
1:1000, Molecular probes). Between incubation steps,
sections were thoroughly washed with PBS and finally
mounted in Vectashield (Vector, Burlingame, CA). All
antibodies were diluted in PBS containing 0.1% bovine
serum albumin, which also served as a negative con-
trol. Sections were examined using a confocal laser-
scanning microscope (Leica, Wetzlar, Germany).
3. Results
Ab-2, a monoclonal antibody directed against α-
synuclein, clearly stained Lewy bodies and Lewy neu-
rites throughout the cingulate cortex (Fig. 1A and
B). Antibodies directed against HS side-chains (JM13,
JM403) and heparinase-digested HSPGs (3G10) in-
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tensely stained both parenchymal and leptomeningeal
vessels. However, no colocalization with α-synuclein
in Lewy bodies and Lewy neurites was observed
(Fig. 1A and B). Senile plaques were observed in only
one PD patient using anti-Aβ antibody 40-4 (Fig. 1(C)).
In contrast to the absence of HSPGs and GAGs in Lewy
bodies and Lewy neurites, senile plaques were clearly
decorated with both JM 403 (data not shown) and 3G10
(Fig. 1D and E). Anti-glypican-1 (S1) and anti-agrin
(JM72) antibodies did not stain Lewy bodies or Lewy
neurites (data not shown). However, JM 72 clearly
stained the basement membranes of cerebral vessels,
indicating that the absence of Lewy bodies and Lewy
neurites staining was not due to technical problems.
4. Discussion
Both Lewy bodies and neurofibrillary tangles are
associated with cytoskeletal changes leading to ac-
cumulation of altered or misfolded proteins. Lewy
bodies and Lewy neurites are characterized by inclu-
sions of aggregated α-synuclein, whereas neurofibril-
lary tangles and dystrophic neurites are composed of
microtubule-associated tau protein. Several studies
demonstrated that heparan sulfate proteoglycans and
heparan sulfate are present in both senile plaques and
tangles, promote Aβ aggregation in vitro, and are in-
volved in the stabilization of these amyloid deposits
by providing protection against proteolytic degrada-
tion and subsequent removal [14,15,19,23,30]. A large
number of components, also observed in association
with senile plaques, including ubiquitin, neurofila-
ments and αB-crystallin have been identified in Lewy
bodies. It is unclear, however, if this is a passive as-
sociation or if these proteins affect α-synuclein fib-
rillogenesis. It has been described that some pesti-
cides and metals may accelerate the rate of formation
of α-synuclein fibrils in vitro [24]. Recently, it was
found that tissue transglutaminase, by cross-linking α-
synuclein, contributed to the generation of α-synuclein
aggregates [16].
Relatively little is known about the role of hep-
aran sulfate proteoglycans in α-synuclein fibrillogen-
esis [21]. Recently, Cohlberg and colleagues demon-
strated that glycosaminoglycans, in particular hep-
aran sulfate, heparin and other highly sulfated compo-
nents, stimulated the formation of α-synuclein fibrils
in vitro [4]. Apart from its catalytic function, hep-
arin was also incorporated into the fibrils. Based on
the binding of basic fibroblast growth factor to hepari-
nase sensitive sites in Lewy bodies, it was suggested
that Parkinson disease-associated Lewy bodies contain
heparan sulfate proteoglycans [19]. Additionally, sev-
eral chondroitin sulfate proteoglycan subtypes accu-
mulated in Lewy bodies [9]. We were unable to con-
firm the accumulation of heparan sulfate proteogly-
cans/glycosaminoglycans in Lewy bodies and Lewy
neurites, suggesting that these sulfated molecules, in
contrast to their role in AD pathology, are not involved
in α-synuclein fibrillization and stabilization, suggest-
ing that the binding of basic fibroblast growth factor
to Lewy bodies may be based on a different type of
interaction than the binding to heparan sulfate proteo-
glycans. In line with our previous observations that
heparan sulfate proteoglycans are observed in senile
plaques in AD brains (reviewed in [29]), we demon-
strated that heparan sulfate proteoglycans and hep-
aran sulfate colocalized with extracellular Aβ in senile
plaques in PD brains. Furthermore, we previously have
demonstrated that heparan sulfate proteoglycans accu-
mulate in intracellular tangles [30]. Given the absence
of heparan sulfate proteoglycans in Lewy bodies, the
present study suggests that heparan sulfate proteogly-
cans are not always associated with any type of intracel-
lular protein aggregation. In this respect, the pathogen-
esis of α-synuclein aggregation seems to differ from
that of tau aggregation.
Although we cannot exclude that heparan sulfate
proteoglycans and heparan sulfate are involved in early
stages of Lewy bodies formation, such an involvement
was not observed in post-mortem material as a clear
colocalization, indicating that either Lewy body for-
mation is independent of the presence of heparan sul-
fate proteoglycans and heparan sulfate, or that the early
stages of Lewy body formation are not represented in
our material. Therefore, future research, e.g. using an-
imal models, is warranted to provide more insight into
the exact mechanism of α-synuclein fibrillization and
a possible role of heparan sulfate proteoglycans and
glycosaminoglycans.
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